ACC.24 Science Preview | Thoraxcenter

View from the Thoraxcenter: ACC.24 Late-breaking Science Preview

Average (ratings)

No ratings

•

Your rating

What’s hot at ACC.24?

Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.

This preview episode of View from the Thoraxcenter offers a critical analysis of the most anticipated trials of ACC.24, highlighting their context and relevance for practice.

Trials covered include:
0:42 - IVUS-ACS: Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes
2:22 - Ultimate DAPT: One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes
4:02 - RELIEVE-HF: A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF
6:52 - ORBITA-COSMIC: Coronary Sinus Reducer for the Treatment of Refractory Angina
8:52 - EMPACT-MI: Empagliflozin After Acute Myocardial Infarction
10:15 - REDUCE-AMI: Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
12:39 - SMART: Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli
14:44 - DEDICATE-DZHK6: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk
16:56 - PERFORM-TAVR: Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement
18:13 - PREVENT: Preventive PCI or Medical Therapy Alone for Atherosclerotic Coronary Vulnerable Plaques
21:32 - FULL REVASC: Ffr-guidance for complete non-culprit REVASCularization
22:46 - DanGer Shock: Danish-German cardiogenic shock trial
25:18 - TARGET BP I: Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs

Read MoreRead Less

Also listen on

Audio Video

Also listen on

Episodes

Up Next

View from the Thoraxcenter: ACC.24 Wrap Up

EP32 • Apr 15, 2024 • 43m 48s

Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24.

All Episodes

Ep 3: Atrial Fibrillation in Congenital Heart Disease

EP3 • Nov 30, 2021 • 16m 52s

Did you know that atrial arrhythmias are the most common complication in adults with congenital heart disease?

Dr Irene Martin de Miguel (Hospital General Universitario Gregorio Marañón, Madrid, Spain) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr de Miguel provides an overview of the current knowledge of AF in CHD, giving practical recommendations for your everyday practice.

Ep 2: Prognostication of patients with coronary stenoses: pre-and post-PCI

EP02 • Oct 29, 2021 • 20m 38s

Is there enough evidence to support the prognostic value of coronary physiology measurements in pre-and post-PCI settings? Is post-PCI FFR ready for clinical practice?

Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.

Ep 1: Women and Heart Disease

EP1 • Oct 01, 2021 • 44m 44s

Did you know that CV disease is the leading cause of death in women and that women are more likely to die of heart disease compared to men? Dr Erin Michos (John Hopkins Uni, US) and Dr Martha Gulati (Uni of Arizona, US) join us on the inaugural episode of the ECR podcast series to discuss issues surrounding women in heart disease. Together they explore a variety of topics that are addressed in the latest special focus issue in the European cardiology Review journal.

1 2 3 4

Targeting Inflammation in Atherosclerosis: LoDoCo2 Trial

EP8 • Apr 22, 2022 • 5m 3s

In this LoDoCo2 presentation, Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) covers the trial design and main results.

Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Targeting Inflammation in Atherosclerosis: RESCUE Trial

EP7 • Apr 12, 2022 • 4m 22s

Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short podcast.

Targeting Inflammation in Atherosclerosis: CANTOS Trial

EP6 • Apr 12, 2022 • 6m 19s

Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.

Ep 5: Invasive Diagnosis of Coronary Functional Disorders Causing Angina Pectoris

EP5 • Mar 25, 2022 • 29m 28s

Did you know that coronary vasomotion disorders are a frequent cause of angina in patients with non-obstructed coronary arteries? In this month's episode of the ECR podcast, Dr Andreas Seitz and Dr Peter Ong (Robert-Bosch Hospital, Stuttgart, DE) return to discuss their recent article on the diagnosis of coronary disorders which cause angina (https://www.ecrjournal.com/articles/invasive-diagnosis-coronary-functional-disorders-causing-angina-pectoris) from ECR Journal.

Ep 4: The EXCEL Trial: The Interventionalists’ Perspective

EP4 • Jan 28, 2022 • 12m 40s

In this month's featured author episode of the ECR Podcast, interventional fellow Dr George Hunter (Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK) discusses the EXCEL trial from his perspective as a member of the PCI community, based on a recent review paper from the ECR Journal. In this podcast, Dr Hunter discusses the controversy surrounding the trial and the importance of studying left main stem disease in cardiology today.

... 2 3 4 5 6 7